%0 Journal Article %1 sebastian2025p31834 %A Sebastian, M. %A Nordman, I. %A Ürün, Y. %A Voon, P.J %A Isla, D. %A Vera, K. %A Orlandi, F. %A Sansar, B. %A Winckels, S. %A Mueller, C. %A Triebel, F. %B 2025 World Conference on Lung Cancer %D 2025 %I Springer %J Journal of Thoracic Oncology %K Advanced/Metastatic Chemotherapy Immunotherapy NSCLC %N 10, Supplement 1 %P S559-- %R https://doi.org/10.1016/j.jtho.2025.09.1049 %T P3.18.34 TACTI-004, a Phase 3 Trial of Eftilagimod Alfa Plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1St Line NSCLC %U https://www.sciencedirect.com/science/article/pii/S1556086425020994 %V 20 %X Eftilagimod alfa (E), an antigen presenting cell activator, binds to a subset of MHC class II molecules to mediate T cell (CD4/CD8) recruitment/activation. Prior studies in first line (1L) non-small cell lung cancer (NSCLC) (TACTI-002 NCT03625323: combining E + pembrolizumab (P); INSIGHT-003 NCT03252938 combining E with chemotherapy + P SoC) showed encouraging efficacy results across all PD-L1 strata & excellent safety profiles. TACTI-004 is a double-blinded, randomized, placebo-controlled phase 3 study testing E + SoC vs. placebo + SoC in 1L NSCLC patients (pts). %Z IF - 20.8 (2025)

@article{sebastian2025p31834, abstract = {Eftilagimod alfa (E), an antigen presenting cell activator, binds to a subset of MHC class II molecules to mediate T cell (CD4/CD8) recruitment/activation. Prior studies in first line (1L) non-small cell lung cancer (NSCLC) (TACTI-002 [NCT03625323]: combining E + pembrolizumab (P); INSIGHT-003 [NCT03252938] combining E with chemotherapy + P [SoC]) showed encouraging efficacy results across all PD-L1 strata & excellent safety profiles. TACTI-004 is a double-blinded, randomized, placebo-controlled phase 3 study testing E + SoC vs. placebo + SoC in 1L NSCLC patients (pts).}, added-at = {2026-09-02T13:24:27.000+0200}, annote = {IF - 20.8 (2025)}, author = {Sebastian, M. and Nordman, I. and Ürün, Y. and Voon, P.J and Isla, D. and Vera, K. and Orlandi, F. and Sansar, B. and Winckels, S. and Mueller, C. and Triebel, F.}, biburl = {https://www.bibsonomy.org/bibtex/24ff22b061193e2bf90a1409dd5e1a38c/libraryvaranasi}, booktitle = {2025 World Conference on Lung Cancer}, description = {"Scopus, Medline, Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP"}, doi = {https://doi.org/10.1016/j.jtho.2025.09.1049}, interhash = {6ecaa217f98596887e5e6e9398b4f200}, intrahash = {4ff22b061193e2bf90a1409dd5e1a38c}, issn = {1556-0864}, journal = {Journal of Thoracic Oncology}, keywords = {Advanced/Metastatic Chemotherapy Immunotherapy NSCLC}, language = {English}, note = {Abstract | First Published on 23 October 2025}, number = {10, Supplement 1}, pages = {S559--}, publisher = {Springer}, subjectarea = {Medical Oncology}, timestamp = {2026-09-07T12:27:55.000+0200}, title = {P3.18.34 TACTI-004, a Phase 3 Trial of Eftilagimod Alfa Plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1St Line NSCLC}, type = {International}, url = {https://www.sciencedirect.com/science/article/pii/S1556086425020994}, volume = 20, year = 2025 }